Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Kedudukan dalam Saham #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Harga Saham
$8.46
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$514.33M
Perubahan (1 hari)
-2.08%
Perubahan (1 tahun)
128.03%
Negara
US
Perdagangan Kyverna Therapeutics, Inc. (KYTX)

Kategori

Bilangan saham terbitan bagi Kyverna Therapeutics, Inc. (KYTX)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham Kyverna Therapeutics, Inc., bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Kyverna Therapeutics, Inc. (KYTX) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M -
US
62.19M -
NL
478.91M -
AU
396.00M -
US
- -
CH